OS Therapies Incorporated
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | – | – | – | – | |
| – | -98.8% | +0.0% | +424.2% | -34.1% | +13,060,511.5% | |
| – | – | – | – | – | +1,589,895.2% | |
| – | -99.9% | +64.8% | +112.9% | -106.4% | – | |
| – | -99.4% | -100.0% | – | – | – | |
| – | -99.9% | +15.2% | -99.5% | – | – | |
| – | – | – | – | – | – | |
| – | – | – | – | – | – | |
| – | – | +29.6% | -17.4% | -52.5% | -100.0% | |
| – | -99.9% | +19.7% | -21.3% | +344.7% | +73,793.9% | |
| – | -100.1% | – | -246.1% | – | -95,898.6% | |
| – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.